{
    "sec_cik": "0000816284",
    "sec_company_name": "CELGENE CORP /DE/ (Filer)",
    "document_type": "EX991",
    "sec_form_header": "Form 8-K",
    "sec_period_of_report": "20190131",
    "sec_filing_date": "20190131",
    "sec_changed_date": "20190131",
    "sec_accepted_date": "20190131073456",
    "sec_index_url": "https://www.sec.gov//Archives/edgar/data/816284/000110465919004612/0001104659-19-004612-index.htm",
    "sec_url": "https://www.sec.gov//Archives/edgar/data/816284/000110465919004612/0001104659-19-004612.txt",
    "metadata_file_name": "C:\Users\aaron\OneDrive\Desktop\homework\finance2\SEC-EDGAR-text\output_files_examples\batch_0008\003\CELG_0000816284_EX991_20190131_EX-99_metadata.json",
    "original_file_name": "",
    "original_file_size": "676185 chars",
    "document_group": "EX-99",
    "section_name": "EX-99",
    "section_n_characters": 30169,
    "endpoints": [
        "Exhibit 99.1 ",
        "(3) IDHIFAÂ® was approved in August 2017 in the U.S. for the treatment of adult patients with R/R AML with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA approved test."
    ],
    "extraction_method": "html",
    "warnings": [],
    "company_description": "CELG",
    "output_file": "C:\Users\aaron\OneDrive\Desktop\homework\finance2\SEC-EDGAR-text\output_files_examples\batch_0008\003\CELG_0000816284_EX991_20190131_EX-99_excerpt.txt",
    "time_elapsed": 0.3,
    "batch_number": 8,
    "batch_signature": "",
    "batch_start_time": "2023-04-16 22:35:47.811513",
    "batch_machine_id": "DESKTOP-BTCJU5K",
    "section_end_time": "2023-04-16 22:49:59.076605"
}